News Data backs Vertanical's cannabis therapy for back pain A phase 3 trial of Vertanical's cannabis extract in back pain has been published, and the results bode well for marketing applications under review.
News Vertanical's cannabis-based painkiller hits target in trials A cannabis-derived drug developed by Vertanical has shown efficacy in phase 3 for chronic back pain and could reach its first markets soon.
News J&J jumps on the MFN pricing train Johnson & Johnson is the latest pharma group to agree a Most-Favoured Nation (MFN) drug pricing deal with the Trump administration to avert tariffs.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.